HRP20200962T1 - Novi spojevi - Google Patents

Novi spojevi Download PDF

Info

Publication number
HRP20200962T1
HRP20200962T1 HRP20200962TT HRP20200962T HRP20200962T1 HR P20200962 T1 HRP20200962 T1 HR P20200962T1 HR P20200962T T HRP20200962T T HR P20200962TT HR P20200962 T HRP20200962 T HR P20200962T HR P20200962 T1 HRP20200962 T1 HR P20200962T1
Authority
HR
Croatia
Prior art keywords
carboxamide
cyano
pyrrolidine
thiazol
imidazol
Prior art date
Application number
HRP20200962TT
Other languages
English (en)
Inventor
Alison Jones
Mark Ian Kemp
Martin Lee Stockley
Karl Richard Gibson
Gavin Alistair Whitlock
Andrew Madin
Original Assignee
Mission Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Limited filed Critical Mission Therapeutics Limited
Publication of HRP20200962T1 publication Critical patent/HRP20200962T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Claims (18)

1. Spoj formule (I) [image] tautomer istog, ili farmaceutski prihvatljiva sol navedenog spoja ili tautomera, naznačen time da: R1 predstavlja 5 do 10-dijelni heteroarilni prsten; R2, R3, R4, R5, R6 i R8, svaki zasebno, predstavljaju atom vodika, cijano, C1-C3 alkil, C1-C3 alkoksi skupine, ili R2 je povezan s R8 kako bi oblikovali C3-C4 cikloalkilni prsten, ili R6 je povezan s R7 kako bi oblikovali C3-C4 cikloalkilni prsten; naznačen time da navedene alkil, alkoksi i cikloalkil skupine mogu opcionalno biti zamijenjene s jednim ili više supstituenata, koji mogu biti isti ili različiti, odabrani od halo, deutero, C1-3 alkil, C1-3 alkoksi, i cijano; R7 predstavlja atom vodika, atom fluora, cijano, C1-C3 alkil, CF3, C1-C3 alkoksi skupinu ili aril ili heteroarilni prsten ili je povezan s R8 kako bi oblikovao spirocikličnu skupinu ili je povezan s R6 kako bi oblikovao C3-C4 cikloalkilni prsten; naznačen time da R1 može opcionalno biti zamijenjen s jednim ili više od Q1-(R9)n; n je 0 ili 1; Q1 predstavlja atom vodika, halogeni atom, cijano, kovalentnu vezu, -NR10-, -CONR10-, -NR10CO-, atom kisika, okso, nitro, -S(O)m-, C1-C6 alkoksi, C1-C6 haloalkoksi, C1-C6 hidroksialkil, -CO-, -SO2R11, -NR11R12, -NR11COR12, -NR10CONR11R12, -CONR11R12, -CO2R11, -NR11CO2R12, -SO2NR11R12, -C(O)R11, -NR11SO2R12, NR11SO2NR13R14, i SO2NR11, C1-C6 alkilen, -C2-C6 alkenilen, -C1-C6 alkil, ili C1-C2 haloalkilnu skupinu; m je 0, 1 ili 2; R9 predstavlja 3 do 10-dijelni heterociklil, heteroaril, aril ili cikloalkilni prsten; i R10, R11, i R12 svaki zasebno predstavljaju atom vodika, C1-C6 alkil, ili C1-C6 alkilensku skupinu; naznačen time da R9 može opcionalno biti zamijenjen s jednim ili više supstituenata odabranih od halogena, C1-C6 haloalkila, C1-C6 alkoksi, C1-C6 haloalkoksi, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 hidroksialkil, okso, cijano, nitro, heterociklil, cikloalkil, heteroaril, aril, -Q2-NR13CONR14R15, -Q2-NR13R14, -Q2-NR13COR14, -Q2-COR13, -Q2-SO2R13, -Q2-CONR13, Q2-CONR13R14, -Q2-CO2R13, -Q2-SO2NR13R14, -Q2-NR13SO2R14, i -Q2-NR13SO2NR14R15; naznačen time da navedene alkil, alkoksi heteroarilne skupine mogu opcionalno biti zamijenjene s halo, deutero, C1-3 alkil, hidroksi, C1-3 alkoksi, cijano, amino, nitro, okso, aril, heteroaril, heterociklil, C3-C6 cikloalkil, C1-3 alkilamino, C2-6 alkenilamino, di-C1-3 alkilamino, C1-3 acilamino, di-C1-3 acilamino, karboksi, C1-3 alkoksikarbonil, karbamoil, mono-C1-3 karbamoil, di-C1-3 karbamoil ili bilo koji od prethodnih u kojima je hidrokarbilni dio sam zamijenjen s halo; ili R9 može biti zamijenjen s 3 do 10-dijelnim heterociklil, heteroaril, aril ili cikloalkil prstenom, ili izravno pričvršćenim ili putem povezujuće skupine odabrane od kisika, karbonila, opcionalno zamijenjenog C1-C6 alkilena ili opcionalno zamijenjenog C1-C6 alkilenoksi lanca; Q2 predstavlja kovalentnu vezu ili C1-C6 alkilen ili C2-C6 alkilen skupinu; i R13, R14 i R15 svaki zasebno predstavljaju vodik, C1-C6 alkil, heterociklil, heteroaril, aril, ili cikloalkil; naznačen time da navedena alkil skupina može opcionalno biti zamijenjena s halo, deutero, C1-3 alkil , hidroksi, C1-3 alkoksi, cijano, amino, nitro, okso, aril, heteroaril, heterociklil, C3-C6 cikloalkil, C1-3 alkilamino, C2-6 alkenilamino, di-C1-3 alkilamino, C1-3 akilamino, di-C1-3 akilamino, karboksi, C1-3 alkoksikarbonil, karbamoil, mono-C1-3 karbamoil, di-C1-3 karbamoil ili bilo koji od prethodnih u kojima je hidrokarbilni dio sam zamijenjen s halo.
2. Spoj prema zahtjevu 1, naznačen time da je R1 5 do 10-dijelni monociklični ili biciklični heteroarilni prsten koji se sastoji od 1 do 3 heteroatoma zasebno odabrana od dušika, kisika i sumpora, i koji može opcionalno biti zamijenjen s 1 do 4 Q1-(R9)n.
3. Spoj prema bilo kojem od zahtjeva 1 ili zahtjeva 2, naznačen time da je heteroarilni prsten iz R1 5 ili 6-dijelni heteroarilni prsten ili 9-dijelni biciklični heteroarilni prsten.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time da je prsten iz R1 odabran od tiazolila, piridinila, izoksazolila, tiadiazolila, indazolila, imidazolila, benzotiazolila, benzoimidazolila, pirazolila, piridazinila, pirimidinila, naptiridinila, pirazinila, izokvinolinila, kvinolinila, tetrahidrotiazolopiridinila, imidazopiridinila, triazolila, pirazolopiridinila, tetrahidropirazolopirazinila, tetrahidrotiazoloazepinila i tiazolopiridinila.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time da za svaki Q1-(R9)n, gdje je n 0, svaki Q1 supstituent može biti zasebno odabran od halogenog atoma, C1-C4 alkila, C1-C2 haloalkila, C1-C2 alkoksi, -COR11, -SO2R11, cijano, CONR11R12 i C1-C2 haloalkoksi; i naznačen time da za svaki Q1-(R9)n, gdje je n 1, svaki Q1 supstituent može biti zasebno odabran od kovalentne veze, -CO-, C1-C6 alkilena, C2-C6 alkilen skupine, i –NR10.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time da R2 predstavlja vodik, cijano, metil, ili metoksi, pri čemu je metil skupina opcionalno zamijenjena s fluoro, kloro ili metoksi.
7. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time da R7 predstavlja vodik, metil, CF3, fenil, piridil, ili pirimidil.
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da R2, R3, R4, R5, R6, R7 i R8 svaki zasebno predstavljaju vodik.
9. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time da R3 predstavlja metil.
10. Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time da je prsten iz R9 5 ili 6-dijelni monocikličan, ili 9 ili 10-dijelni bicikličan, heterocikličan, arilni, heteroarilni ili cikloalkilni prsten.
11. Spoj prema zahtjevu 10, naznačen time da je prsten iz R9 odabran od morfolinila, piperidnila, pirolidinila, diazepanila, piperazinila, piridazinila, pirazinila, pirazolila, ciklopropila, cikloheksila, ciklopentila, piridinila, imidazolila, indolinila, izoindolinila, pirimidinila, izoksazolila, dihidroidenila, dihidroizokvinolinila, tetrahidropiranila, fenila, oksadiazolila, triazolila, izokvinolinila, indazolila, pirazolopiridinila, pirazolopirimidinila, imidazolpiridinila, imidazopirimidinila, imidazopirazinila, oksazolila i kvinolinila.
12. Spoj prema bilo kojem od zahtjeva 1 do 11, naznačen time da: R9 može opcionalni biti zamijenjen s jednim ili više supstituenata odabranih od halogena, C1-C6 haloalkil, C1-C6 alkoksi, C1-C6 haloalkoksi, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 hidroksialkil, okso, cijano, nitro, heterociklil, cikloalkil, heteroaril, aril, -Q2-NR13CONR14R15, -Q2-NR13R14, -Q2-NR13COR14, -Q2-COR13, -Q2-SO2R13, -Q2-CONR13, Q2-CONR13R14, -Q2-CO2R13, -Q2-SO2NR13R14, -Q2-NR13SO2R14 i -Q2-NR13SO2NR14R15; pri čemu navedene alkil, alkoksi i heteroaril skupine mogu opcionalno biti zamijenjene s halo, deutero, C1-3 alkil, hidroksi, C1-3alkoksi, cijano, amino, nitro, ili okso; ili R9 može biti zamijenjen s 3 do 10-dijelnim heterociklil, heteroaril, aril ili cikloalkil prstenom, ili izravno pričvršćenim ili putem povezujuće skupine odabrane od kisika, karbonila, opcionalno zamijenjenog C1-C6 alkilena ili opcionalno zamijenjenog C1-C6 alkilenoksi lanca; Q2 predstavlja kovalentnu vezu ili C1-C6 alkilen ili C2-C6 alkenilen skupinu; i R13, R14 i R15 svaki zasebno predstavljaju vodik, C1-C6 alkil, heterociklil, heteroaril, aril, ili cikloalkil; pri čemu navedena alkilna skupina može opcionalno biti zamijenjena s halo, deutero, C1-3 alkil, hidroksi, C1-3 alkoksi, cijano, amino, nitro ili okso.
13. Spoj prema zahtjevu 12, naznačen time da R9 može opcionalno biti zamijenjen s 1 do 3 supstituenta, odabrana od halogena, C1-C6 haloalkil, C1-C6 alkoksi, C1-C6 haloalkoksi, C1-C6 alkil, C2-C6 alkinil, okso, cijano, cikloalkil, heteroaril, NR13R14, NR13COR14, CH2NR13COR14, COR13, CONR13R14, SO2NR13R14, i NR13SO2R14; ili R9 može biti zamijenjen s 3 do 10-dijelnim heterociklil, heteroaril, aril ili cikloalkil prstenom, ili izravno pričvršćenim ili putem povezujuće skupine odabrane od kisika, karbonila, opcionalno zamijenjenog C1-C6 alkilena ili opcionalno zamijenjenog C1-C6 alkilenoksi lanca; i R13, R14 i R15 svaki zasebno predstavljaju vodik, C1-C6 alkil, ili fenil.
14. Spoj prema bilo kojem od zahtjeva 1 do 13, imajući formulu (IV), [image] tautomer istog, ili farmaceutski prihvatljiva sol navedenog spoja ili tautomera; naznačen time da Y predstavlja preostale atome 5 ili 6-dijelnog heteroaril prstena koji može opcionalno biti zamijenjen ili spojen s daljnjim prstenom, koji može dalje opcionalno biti zamijenjen, naznačen time da su navedeni opcionalni supstituenti kao što je određeno u bilo kojem od zahtjeva 1 do 13.
15. Spoj prema zahtjevu 1, koji je odabran od skupine koja se sastoji od: (S)-1-cijano-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(3-fluorofenil)tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(2-fluorofenil)tiazol-2-il)pirolidin-3-karboksamid; N-(5-(4-klorofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; N-(5-(3-klorofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; N-(5-(2-klorofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(5-metiltiazol-2-il)pirolidin-3-karboksamid; N-(5-(tert-butil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(4-feniltiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(2-feniltiazol-5-il)pirolidin-3-karboksamid; 1-cijano-N-(5-fenil-1,3,4-tiadiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-etil-1,3,4-tiadiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(3-fenilizoksazol-5-il)pirolidin-3-karboksamid; 1-cijano-N-(3-(4-metoksifenil)izoksazol-5-il)pirolidin-3-karboksamid; 1-cijano-N-(5-fenilizoksazol-3-il)pirolidin-3-karboksamid; N-(5-(tert-butil)izoksazol-3-il)-1-cijanopirolidin-3-karboksamid; N-(3-(tert-butil)-1H-pirazol-5-il)-1-cijanopirolidin-3-karboksamid; N-(benzo[d]tiazol-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(6-metilbenzo[d]tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(6-(trifluorometil)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(6-metoksibenzo[d]tiazol-2-il)pirolidin-3-karboksamid; N-(6-bromobenzo[d]tiazol-2-il)-1-cijanopirolidin-3-karboksamid; N-(1H-benzo[d]imidazol-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(piridin-2-il)pirolidin-3-karboksamid; N-(5-kloropiridin-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(5-metilpiridin-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-metoksipiridin-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-morfolinopiridin-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(piperidin-1-il)piridin-2-il)pirolidin-3-karboksamid; N-(5-(1H-imidazol-1-il)piridin-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(4-fenilpiridin-2-il)pirolidin-3-karboksamid; N-([2,3’-bipiridin]-6’-il)-1-cijanopirolidin-3-karboksamid; N-([3,3’-bipiridin]-6-il)-1-cijanopirolidin-3-karboksamid; N-([3,4’-bipiridin]-6-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(6-fenilpiridin-3-il)pirolidin-3-karboksamid; 1-cijano-N-(6-fenilpiridazin-3-il)pirolidin-3-karboksamid; 1-cijano-N-(2-fenilpirimidin-5-il)pirolidin-3-karboksamid; 1-cijano-N-(5-cikloheksilpiridin-2-il)pirolidin-3-karboksamid; N-(1-benzil-1H-indazol-5-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(1-propil-1H-benzo[d]imidazol-5-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-fenil-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-fenil-1H-pirazol-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(tetrahidro-2H-piran-4-il)-1H-pirazol-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-fenil-1H-1,2,3-triazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-fenil-1H-pirazol-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-metilbenzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(7-metilbenzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-N-(4-bromobenzo[d]tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(imidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid; (S)-N-(7-bromoimidazo[1,2-a]piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(6-bromoimidazo[1,2-a]piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(pirazolo[1,5-a]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-metoksipiridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-fenilpiridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-fenilpiridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1,8-naftiridin-2-il)pirolidin-3-karboksamid; (S)-N-(5-benziltiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(izokvinolin-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(tetrahidro-2H-piran-4-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-metil-5-fenil-1H-pirazol-3-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(4-metoksipiperidin-1-il)piridin-2-il)pirolidin-3-karboksamid; (S)-N-(6-(1H-1,2,3-triazol-1-il)benzo[d]tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(6-(2H-1,2,3-triazol-2-il)benzo[d]tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-(metilkarbamoil)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-metil-5-(morfolinometil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-fluorofenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3,4-difluorofenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-(trifluorometil)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(piridin-4-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(piridin-2-il)tiazol-2-il)pirolidin-3-karboksamid; (R)-1-cijano-N-(5-fenilpiridin-2-il)pirolidin-3-karboksamid; (2S,3S)-1-cijano-2-metil-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; (2S,3S)-1-cijano-N-(5-(4-fluorofenil)tiazol-2-il)-2-metilpirolidin-3-karboksamid; (2S,3S)-1-cijano-2-metil-N-(1-fenil-1H-imidazol-4-il)pirolidin-3-karboksamid; (2S,3S)-1-cijano-2-metil-N-(5-fenil-1H-pirazol-3-il)pirolidin-3-karboksamid; (2S,3S)-1-cijano-2-metil-N-(5-(tetrahidro-2H-piran-4-il)tiazol-2-il)pirolidin-3-karboksamid; (2S,3S)-N-(5-(2-klorofenil)tiazol-2-il)-1-cijano-2-metilpirolidin-3-karboksamid; 1-cijano-3-metil-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; 1-cijano-3-metil-N-(1-fenil-1H-imidazol-4-il)pirolidin-3-karboksamid; 1-cijano-3-(metoksimetil)-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; 1,3-dicijano-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; (3S,4S)-1-cijano-4-metil-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; (3 S,4S)-1-cijano-4-metil-N-(5-metiltiazol-2-il)pirolidin-3-karboksamid; (3S,4S)-N-(5-(2-klorofenil)tiazol-2-il)-1-cijano-4-metilpirolidin-3-karboksamid; (3S,4S)-1-cijano-4-metil-N-(1-fenil-1H-imidazol-4-il)pirolidin-3-karboksamid; (3S,4S)-1-cijano-4-etil-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; (3S,4S)-1-cijano-4-etil-N-(1-fenil-1H-imidazol-4-il)pirolidin-3-karboksamid; 1-cijano-5-metil-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; 1-cijano-5-metil-N-(1-fenil-1H-imidazol-4-il)pirolidin-3-karboksamid; 1-cijano-5-metil-N-(5-fenil-1H-pirazol-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-morfolinotiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(4-metilpiperazin-1-il)tiazol-2-il)pirolidin-3-karboksamid; N-(5-(2-(acetamidometil)piperidin-1-il)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(5-(metil(fenil)amino)tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(indolin-1-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(piperidin-1-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(izoindolin-2-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3,4-dihidroizokvinolin-2(1H)-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-((R)-2-(metoksimetil)pirolidin-1-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-((S)-2-(metoksimetil)pirolidin-1-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(5-okso-1,4-diazepan-1-il)tiazol-2-il)pirolidin-3-karboksamid; (R)-1-cijano-N-(5-morfolinotiazol-2-il)pirolidin-3-karboksamid; (R)-1-cijano-N-(5-(piperidin-1-il)tiazol-2-il)pirolidin-3-karboksamid; (3S,4S)-1-cijano-4-metil-N-(5-(piperidin-1-il)tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-5-metil-N-(5-(piperidin-1-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(pirolidin-1-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(pirolidin-1-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(pirolidin-1-il)pirazin-2-il)pirolidin-3-karboksamid; N-(5-(2-aminofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; N-(5-(3-aminofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; N-(5-(4-aminofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(5-(piridin-3-il)tiazol-2-il)pirolidin-3-karboksamid; (E)-1-cijano-N-(5-(2-ciklopropilvinil)tiazol-2-il)pirolidin-3-karboksamid; N-(5-(4-acetamidofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; N-(5-(2-acetamidofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; 1-cijano-N-(5-(3-(metilsulfonamido)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3-cijanofenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-cijanofenil)tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(3,5-dimetilizoksazol-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(4-metoksifenil)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-fenilbenzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(1-metil-1H-pirazol-5-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(1-metil-1H-pirazol-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,5-dimetil-1H-pirazol-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(5-metilizoksazol-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(7-(3,5-dimetilizoksazol-4-il)imidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)imidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-ciklopropilimidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid 1-cijano-N-(6-ciklopropilbenzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,6-dimetoksipiridazin-4-il)imidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,6-dimetoksipiridazin-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (2S,3S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)benzo[d]tiazol-2-il)-2-metilpirolidin-3-karboksamid; 1-cijano-N-(5-(p-tolil)piridin-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(m-tolil)piridin-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(o-tolil)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)-5-metilimidazo[1,2-a]piridin-2-il)pirolidin-3 -karboksamid; (S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)-7-metilbenzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(7-metil-6-(1-metil-1H-pirazol-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(morfolinometil)tiazol-2-il)pirolidin-3-karboksamid; 1-cijano-N-(5-(pirolidin-1-ilmetil)tiazol-2-il)pirolidin-3-karboksamid; (3S)-1-cijano-N-(5-((2,6-dimetilmorfolino)metil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(((R)-2-(metoksimetil)pirolidin-1-il)metil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(((S)-2-(metoksimetil)pirolidin-1-il)metil)tiazol-2-il)pirolidin-3-karboksamid; (2S,3S)-1-cijano-N-(5-(((R)-2-(metoksimetil)pirolidin-1-il)metil)tiazol-2-il)-2-metilpirolidin-3-karboksamid; (S)-N-(1-benzil-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(1-fenetil-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-izobutil-1H-imidazol-4-il)pirolidin-3-karboksamid; (2S,3S)-N-(1-benzil-1H-imidazol-4-il)-1-cijano-2-metilpirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-fluorofenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(3-fluorofenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-fluorofenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-(trifluorometil)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(3-(trifluorometil)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-(metilkarbamoil)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(3-(metilkarbamoil)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-(metilkarbamoil)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-((2-metoksietil)karbamoil)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-metoksifenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-metoksifenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(tetrahidro-2H-piran-4-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-cikloheksil-1H-imidazol-4-il)pirolidin-3-karboksamid; (3S)-1-cijano-N-(1-(2,3-dihidro-1H-inden-1-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2,3-dihidro-1H-inden-2-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-((tetrahidro-2H-piran-4-il)metil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-((S)-1-feniletil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-((R)-1-feniletil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(piridin-2-ilmetil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(piridin-3-ilmetil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(piridin-4-ilmetil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-((3,5-dimetilizoksazol-4-il)metil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (2S,3S)-1-cijano-2-metil-N-(1-((S)-1-feniletil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (3S,4S)-1-cijano-4-metil-N-(1-((S)-1-feniletil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-metilpiridin-2-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(6-metilpiridin-2-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (R)-1-cijano-N-(1-(2-metilpirimidin-4-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijanofenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-N-(1-benzil-2-metil-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-(3,5-dimetilizoksazol-4-il)etil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(3-cijanofenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(piridin-3-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(piridin-4-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(3-metoksifenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (3S)-N-(1-(1-benzoilpiperidin-3-il)-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (3S)-N-(1-(1-benzoilpirolidin-3-il)-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (3S)-N-(1-(1-benzilpiperidin-3-il)-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (3S)-1-cijano-N-(1-(1-metilpiperidin-3-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (3S)-1-cijano-N-(1-(1-metilpirolidin-3-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-N-(5-acetil-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-izobutiril-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-N-(5-benzoil-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(2-metoksibenzoil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-picolinoil-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(1-metil-1H-pirazol-3-karbonil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(1-metil-2-okso-1,2-dihidropiridin-3-karbonil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-nikotinoil-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(dimetilglicil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; metil(S)-2-(1-cijanopirolidin-3-karboksamido)-6,7-dihidrotiazolo[5,4-c]piridin-5(4H)-karboksilat; 2-metoksietil(S)-2-(1-cijanopirolidin-3-karboksamido)-6,7-dihidrotiazolo[5,4-c]piridin-5(4H)-karboksilat; (S)-1-cijano-N-(5-metil-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-N-(5-benzil-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(metilsulfonil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(izopropilsulfonil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(fenilsulfonil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-etinilfenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3-etinilfenil)tiazol-2-il)pirolidin-3-karboksamid; (3S)-1-cijano-N-(5-(N-(1-feniletil)sulfamoil)piridin-2-il)pirolidin-3-karboksamid; (3S)-1-cijano-N-(5-(N-metil-N-(1-feniletil)sulfamoil)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(5-metil-1,2,4-oksadiazol-3-il)imidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid; (3S,4S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)imidazo[1,2-a]piridin-2-il)-4-(trifluorometil)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(1-metil-1H-pirazol-4-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(N,N-dimetilsulfamoil)-4,5,6,7-tetrahidrotiazolo[5,4-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(piridazin-4-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-cijano-3-fluorofenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-N-(5-(1H-indazol-7-il)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(5-(3-(1H-imidazol-1-il)fenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-(metilsulfonamido)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-N-(5-(3-(1H-pirazol-1-il)fenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-cijano-3-(trifluorometoksi)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-cijano-3-metoksifenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-sulfamoilfenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-N-(5-(1H-indazol-6-il)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(5-(1H-indazol-5-il)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-6-(2-(1-cijanopirolidin-3-karboksamido)tiazol-5-il)-N-metilpicolinamid; (S)-6-(2-(1-cijanopirolidin-3-karboksamido)tiazol-5-il)-N-etilpicolinamid; (S)-1-cijano-N-(5-(1-metil-1H-indazol-5-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(1-(2-metoksietil)-1H-indazol-5-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(2-oksoindolin-7-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3-metil-1H-indazol-5-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-N-(5-(1H-indazol-4-il)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(4-fluoro-3-(metilkarbamoil)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-N-(5-(3-karbamoilfenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3-(metilkarbamoil)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3-(etilkarbamoil)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3-(dimetilkarbamoil)fenil)tiazol-2-il)pirolidin-3-karboksamid; (S)-N-(5-(3-karbamoil-4-fluorofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(5-(3-karbamoil-4-klorofenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(5-(4-kloro-3-(metilkarbamoil)fenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(5-(4-kloro-3-(prop-2-in-1-ilkarbamoil)fenil)tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(5-(izopropilsulfonil)-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-fenil-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-2-il)pirolidin-3-karboksamid; (S)-N-(5-benzil-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-(2-metoksietoksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-cijano-5-(2-metoksietoksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-(3-morfolinopropoksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-cijano-5-(3-morfolinopropoksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-(((S)-tetrahidrofuran-3-il)oksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-cijano-5-(((S)-tetrahidrofuran-3-il)oksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-(oksetan-3-iloksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(2-cijano-5-(oksetan-3-iloksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(pirazolo[1,5-a]pirimidin-7-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(imidazo[1,2-a]pirimidin-5-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(imidazo[1,2-a]piridin-5-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(imidazo[1,2-a]pirazin-6-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(imidazo[1,2-a]pirimidin-6-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1,7-naftiridin-6-il)pirolidin-3-karboksamid; (S)-N-(6-(3-klorofenil)pirimidin-4-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(2’-amino-[4,4’-bipiridin]-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(2’-(metilamino)-[4,4’-bipiridin]-2-il)pirolidin-3-karboksamid; (S)-3-(1-cijanopirolidin-3-karboksamido)-N-metilizokvinolin-6-karboksamid; (S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)izokvinolin-3-il)pirolidin-3-karboksamid; (S)-N-(4-(1H-indazol-4-il)piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(6-etinilizokvinolin-3-il)pirolidin-3-karboksamid ; (2S,3S)-1-cijano-N-(6- etinilizokvinolin-3-il)-2-metilpirolidin-3-karboksamid; (S)-3-(1-cijanopirolidin-3-karboksamido) izokvinolin-6-karboksamid; (2S,3S)-N-(6-(1H-pirazol-4-il)izokvinolin-3-il)-1-cijano-2-metilpirolidin-3-karboksamid; (S)-1-cijano-N-(pirazolo[1,5-a]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-fenilpiridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(piridin-3-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(piridin-3-il)tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(trifluorometil)imidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-metil-5-(m-tolil)-1H-pirazol-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(kvinolin-3-il)pirolidin-3-karboksamid; (S)-N-(4-(tert-butil)piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(6-(piridin-4-il)pirimidin-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-fenilpiridazin-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(oksazol-5-il)imidazo[1,2-a]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(izopropilsulfonil)-5,6,7,8-tetrahidro-4H-tiazolo[4,5-d]azepin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-(1-(2-metoksietil)-1H-pirazol-4-il)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; 3-cijano-N-(5-feniltiazol-2-il)-3-azabiciklo[3.1.0]heksan-1-karboksamid; 2-cijano-N-(5-feniltiazol-2-il)-2-azabiciklo[3.1.0]heksan-4-karboksamid; (3S,4S)-1-cijano-N-(5-feniltiazol-2-il)-4-(trifluorometil)pirolidin-3-karboksamid; (3S,4R)-1-cijano-N-(5-feniltiazol-2-il)-4-(piridin-3-il)pirolidin-3-karboksamid; (3S,4R)-1-cijano-N-(5-feniltiazol-2-il)-4-(pirimidin-5-il)pirolidin-3-karboksamid; 1-cijano-3-metoksi-N-(5-feniltiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)tiazolo[4,5-b]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(5-(3,5-dimetilizoksazol-4-il)tiazolo[5,4-b]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(2,6-dimetilfenil)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(1,3-dimetil-1H-pirazol-4-il)benzo[d]tiazol-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(5-(trifluorometil)-1H-pirazol-4-il)izokvinolin-3-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(4-(3-(5-metilizoksazol-4-il)fenil)piridin-2-il)pirolidin-3-karboksamid; (S)-N-(4-(1H-pirazol-4-il)piridin-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(6-(1H-pirazol-4-il)benzo[d]tiazol-2-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(1-(4-(1H-pirazol-4-il)fenil)-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(4-(5-metil-1H-pirazol-4-il)piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(6-(3,5-dimetilizoksazol-4-il)tiazolo[4,5-c]piridin-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(2’-(5-metilizoksazol-4-il)-[4,4’-bipiridin]-2-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(1,3-dimetil-1H-indazol-5-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(3-metil-1H-indazol-6-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-5-il)-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (S)-N-(1-(1H-indazol-6-il)-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-fluoro-3-metoksifenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-N-(1-(1H-indazol-4-il)-1H-imidazol-4-il)-1-cijanopirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-ciklopropilfenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(kvinolin-4-il)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-metil-N-(4-(4-(metilkarbamoil)fenil)tiazol-2-il)pirolidin-2-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-metoksifenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-metilfenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; (S)-1-cijano-N-(1-(4-cijano-3-(trifluorometil)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; i (S)-1-cijano-N-(1-(4-cijano-3-(trifluorometoksi)fenil)-1H-imidazol-4-il)pirolidin-3-karboksamid; tautomer istog, ili farmaceutski prihvatljiva sol navedenog spoja ili tautomera.
16. Spoj prema bilo kojem od zahtjeva 1 do 15, tautomer istog, ili farmaceutski prihvatljiva sol navedenog spoja ili tautomera, za korištenje kao lijek.
17. Spoj prema bilo kojem od zahtjeva 1 do 15, tautomer istog, ili farmaceutski prihvatljiva sol navedenog spoja ili tautomera, za korištenje u liječenju raka, neurodegenerativnih poremećaja, COPD, upala, virusnih ili bakterijskih infekcija ili poremećaja metabolizma.
18. Farmaceutski sastav koji sadrži spoj formule (I) kao što je određen u bilo kojem od zahtjeva 1 do 15, tautomer istog, ili farmaceutski prihvatljiva sol navedenog spoja ili tautomera, zajedno s jednom ili više farmaceutski prihvatljivih pomoćnih tvari.
HRP20200962TT 2014-09-23 2020-06-17 Novi spojevi HRP20200962T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416754.8A GB201416754D0 (en) 2014-09-23 2014-09-23 Novel compounds
EP15774652.0A EP3197883B1 (en) 2014-09-23 2015-09-22 Novel compounds
PCT/GB2015/052729 WO2016046530A1 (en) 2014-09-23 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
HRP20200962T1 true HRP20200962T1 (hr) 2020-10-02

Family

ID=51869322

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200962TT HRP20200962T1 (hr) 2014-09-23 2020-06-17 Novi spojevi

Country Status (23)

Country Link
US (5) US9926307B2 (hr)
EP (2) EP3828179A1 (hr)
JP (3) JP6549703B2 (hr)
KR (1) KR102493967B1 (hr)
CN (2) CN111592534B (hr)
AU (1) AU2015323572B2 (hr)
CA (1) CA2958262C (hr)
CY (1) CY1122983T1 (hr)
DK (1) DK3197883T3 (hr)
ES (1) ES2798473T3 (hr)
GB (1) GB201416754D0 (hr)
HR (1) HRP20200962T1 (hr)
HU (1) HUE050732T2 (hr)
IL (1) IL250345B (hr)
LT (1) LT3197883T (hr)
MX (1) MX2017003358A (hr)
PL (1) PL3197883T3 (hr)
PT (1) PT3197883T (hr)
RS (1) RS60468B1 (hr)
RU (1) RU2691389C2 (hr)
SG (1) SG11201700847YA (hr)
SI (1) SI3197883T1 (hr)
WO (1) WO2016046530A1 (hr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016029662B1 (pt) 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) * 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10807945B2 (en) * 2015-06-22 2020-10-20 Sumitomo Dainippon Pharma Co., Ltd. 1,4-disubstituted imidazole derivative
EP3800186A1 (en) * 2015-07-14 2021-04-07 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) * 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
EP3433246B1 (en) 2016-03-24 2022-05-04 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
WO2017184751A1 (en) * 2016-04-20 2017-10-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing hypertension
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2018060689A1 (en) * 2016-09-27 2018-04-05 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
CN110198937A (zh) * 2017-02-14 2019-09-03 华东理工大学 N-(5-吗啉代噻唑-2-基)甲酰胺类化合物及其制备方法和用途
WO2018209132A1 (en) 2017-05-10 2018-11-15 Cortexyme, Inc. Aminopyridine compounds and methods for the preparation and use thereof
GB201708652D0 (en) * 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
US11059809B2 (en) 2017-06-20 2021-07-13 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as DUB inhibitors
HRP20230251T1 (hr) * 2017-08-01 2023-04-14 Merck Patent Gmbh Derivati tiazolopridina kao antagonisti adenozinskih receptora
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治***的活性化合物
CN111148743B (zh) 2017-10-06 2023-12-15 福马治疗有限公司 抑制泛素特异性肽酶30
WO2019079626A1 (en) * 2017-10-19 2019-04-25 Samumed, Llc 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
WO2019084497A1 (en) * 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
AR114422A1 (es) 2018-03-30 2020-09-02 Syngenta Participations Ag Compuestos herbicidas
JP7449242B2 (ja) * 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
JP2021534122A (ja) * 2018-08-09 2021-12-09 ヴァロ アーリー ディスカバリー， インコーポレイテッド 脱ユビキチン化酵素ｕｓｐ２５及びｕｓｐ２８の阻害
EP3837262A1 (en) 2018-08-14 2021-06-23 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CA3110113A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
UY38435A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
KR102397752B1 (ko) * 2019-06-19 2022-05-16 주식회사 엘지화학 인돌 또는 인다졸 화합물의 제조방법
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
AU2021253617A1 (en) 2020-04-08 2022-12-01 Mission Therapeutics Limited N-cyanopyrrolidines with activity as USP30 inhibitors
BR112022020644A2 (pt) 2020-05-28 2022-12-06 Mission Therapeutics Ltd Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial
US20230234967A1 (en) * 2020-05-28 2023-07-27 Senda Biosciences, Inc. Fused Azole Heterocycles as AHR Antagonists
EP4161920A1 (en) 2020-06-04 2023-04-12 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
CA3186148A1 (en) 2020-06-08 2021-12-16 Mission Therapeutics Limited 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
TW202402754A (zh) * 2021-03-04 2024-01-16 美商美國禮來大藥廠 Fgfr3抑制劑化合物
CA3224123A1 (en) * 2021-07-26 2023-02-02 James Griffin Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US6410561B1 (en) 1998-03-26 2002-06-25 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
WO2001077073A1 (en) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
JP2007529496A (ja) 2004-03-19 2007-10-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
WO2010052222A1 (en) 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
JP5743897B2 (ja) 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
WO2012040527A2 (en) * 2010-09-24 2012-03-29 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
SG11201401608PA (en) * 2011-10-19 2014-07-30 Vivolux Ab Method for inhibition of deubiquitinating activity
JP6397407B2 (ja) 2012-07-19 2018-09-26 ドレクセル ユニバーシティ 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド
JP2016523517A (ja) 2013-05-02 2016-08-12 イー３エックス バイオ インコーポレイテッド ユビキチンリガーゼのモジュレーターを同定するための方法
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
EP3800186A1 (en) 2015-07-14 2021-04-07 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
LT3197883T (lt) 2020-07-10
RU2017105296A (ru) 2018-10-24
KR102493967B1 (ko) 2023-01-31
KR20170055499A (ko) 2017-05-19
AU2015323572A1 (en) 2017-03-23
US20190330202A1 (en) 2019-10-31
ES2798473T3 (es) 2020-12-11
DK3197883T3 (da) 2020-06-22
JP6959299B2 (ja) 2021-11-02
US11472798B2 (en) 2022-10-18
US10392380B2 (en) 2019-08-27
WO2016046530A1 (en) 2016-03-31
BR112017005887A2 (pt) 2017-12-12
PL3197883T3 (pl) 2020-10-19
EP3197883A1 (en) 2017-08-02
IL250345A0 (en) 2017-03-30
JP2019178161A (ja) 2019-10-17
MX2017003358A (es) 2017-09-13
JP7261264B2 (ja) 2023-04-19
IL250345B (en) 2019-05-30
US10774078B2 (en) 2020-09-15
US20170247365A1 (en) 2017-08-31
SG11201700847YA (en) 2017-04-27
JP2017530960A (ja) 2017-10-19
RS60468B1 (sr) 2020-07-31
US20180162852A1 (en) 2018-06-14
SI3197883T1 (sl) 2020-08-31
GB201416754D0 (en) 2014-11-05
CN107001339B (zh) 2020-03-17
RU2691389C2 (ru) 2019-06-13
HUE050732T2 (hu) 2021-01-28
US9926307B2 (en) 2018-03-27
EP3197883B1 (en) 2020-03-18
US20230052191A1 (en) 2023-02-16
CA2958262C (en) 2023-02-14
CA2958262A1 (en) 2016-03-31
CY1122983T1 (el) 2021-10-29
EP3828179A1 (en) 2021-06-02
CN107001339A (zh) 2017-08-01
JP6549703B2 (ja) 2019-07-24
CN111592534B (zh) 2023-06-30
CN111592534A (zh) 2020-08-28
RU2017105296A3 (hr) 2019-01-22
PT3197883T (pt) 2020-06-22
US20200369658A1 (en) 2020-11-26
JP2021138734A (ja) 2021-09-16
AU2015323572B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
HRP20200962T1 (hr) Novi spojevi
JP2017530960A5 (hr)
AU2016222468B2 (en) SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
HRP20210791T2 (hr) 1-cijano-pirolidin spojevi kao usp30 inhibitori
JP2020514267A5 (hr)
CN102007125B (zh) 稠合杂环衍生物及使用方法
JP2018510183A5 (hr)
JP2016523911A5 (hr)
JP2018500376A5 (hr)
JP2018527353A5 (hr)
HRP20160744T2 (hr) Heterocikličke tvari i njihova uporaba kao modulatora receptora tirozin kinaza tipa iii
KR20150002573A (ko) 벤조티아졸-6-일 아세트산 유도체 및 ｈｉｖ 감염을 치료하기 위한 이의 용도
JP2016500073A5 (hr)
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
US20170107204A1 (en) Trka kinase inhibitors, compositions and methods thereof
JP2016507551A5 (hr)
CN111868037B (zh) 作为crhr2拮抗剂的稠合环状脲衍生物
US20170158698A1 (en) TrKA Kinase Inhibitors, Compositions and Methods Thereof
IL272952B2 (en) Modified derivatives of 2-aza-bicyclo[3.1.1]-heptane and 2-aza-bicyclo[3.2.1]-octane as orexin receptor blockers
JPWO2019089670A5 (hr)
JPWO2019198692A5 (hr)
RU2020134947A (ru) Производные конденсированной циклической мочевины в антагонист crhr2
WO2023139085A1 (en) New benzimidazole pyridine derivatives
BR112017005887B1 (pt) Composto, método para produção e uso do mesmo, bem como composição farmacêutica